Mahmoud A. Al-Sha'er

Learn More
Heat shock protein (Hsp90α) has been recently implicated in cancer prompting several attempts to discover and optimize new Hsp90α inhibitors. Toward this end, we explored the pharmacophoric space of 83 Hsp90α inhibitors using six diverse sets of inhibitors to identify high-quality pharmacophores. Subsequently, genetic algorithm and multiple linear(More)
Epidemiological studies have established an inverse relationship between plasma high-density lipoprotein (HDL) cholesterol concentration, and incidence of coronary artery disease (CAD); thus, the development of novel therapies that attempt to exploit the atheroprotective functions of HDL is a major goal. Inhibition of cholesteryl ester transfer protein(More)
As incidence rate of type II diabetes mellitus continues to rise, there is a growing need to identify novel therapeutic agents with improved efficacy and reduced side effects. Dipeptidyl peptidase IV (DPP IV) is a multifunctional protein involved in many physiological processes. It deactivates the natural hypoglycemic incretin hormone effect. Inhibition of(More)
The anticancer activity of thiamine (vitamin B1) combined with its structural properties and docking studies suggested potential anti-heat shock protein 90α (Hsp90α) activity for this vitamin. In experimental testing, thiamine illustrated anti-Hsp90α IC50 value of 12.5 μM. Therefore, in an attempt to capitalize on the simple structure of thiamine and(More)
  • 1